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A B S T R A C T   
The impact of fungal infections on humans is a serious public health issue that has received much less attention 
than bacterial infection and treatment, despite ever-increasing incidence exacerbated by an increased incidence 
of immunocompromised individuals in the population. Candida species, in particular, cause some of the most 
prevalent hospital-related fungal infections. Fungal infections are also detrimental to the well-being of grazing 
livestock, with milk production in dairy cows, and body and coat condition adversely affected by fungal in-
fections. Fungal cell walls are essential for viability, morphogenesis and pathogenesis: numerous anti-fungal 
drugs rely on targeting either the cell wall or cell membrane, but the pipeline of available bioactives is 
limited. There is a clear and unmet need to identify novel targets and develop new classes of anti-fungal agents. 
This mini review focuses on fungal cell wall structure, composition and biosynthesis in Candida spp., including 
C. auris. In addition, an overview of current advances in the development of cell wall targeted therapies is 
considered.   
Introduction 
The widespread use of antifungals in agricultural and clinical settings 
has led to the emergence of drug-resistant fungal infections, which 
represent major threats to food security and human health (Nguyen 
et al., 2021). Despite the high mortality and morbidity rate of invasive 
fungal infections (IFIs), treatment options are limited and the anti- 
fungal drug discovery pipeline is under developed (Perfect, 2017). 
There are three main classes of available anti-fungal agents to treat IFI: 
the first class of antifungal agents, azoles (e.g. fluconazole, itraconazole) 
inhibit the ergosterol biosynthesis of fungal cell wall. There is a signif-
icant overlap in the use of azoles to treat both human and plant fungal 
pathogens. They are widely used in grain- and grass-growing environ-
ments, as well as clinical settings, to control Candida spp., Aspergillus 
spp. and Cryptococcus spp. infections (Azevedo et al., 2015). The second 
class of antifungal agents, polyene amphotericin B-deoxycholate bind 
directly to ergosterol embedded in the fungal cell membrane, leading to 
cell lysis. The third class, echinocandins (caspofungin, micafungin, 
anidulafungin and rezafungin), inhibit fungal β-(1,3)-D-glucan cell wall 
biosynthesis (Gow et al., 2017). Along with those three classes of 
antifungal agents, the pro-drugs and 5-fluorocytosine/ flucytosine 
(FLC), an antimetabolite, act as antifungal agents. FLC, within suscep-
tible fungal cells, is converted into fluorouracil by cytosine deaminase 
(CD), resulting in inhibition of fungal RNA and DNA synthesis (Nechi-
padappu et al., 2018). 
Discovering new drugs for the treatment of resistant IFIs is chal-
lenging due to difficulties with poor drug uptake, limiting access to 
intracellular targets (Perlin, 2007). Herein we review the cell wall 
composition across Candida species and opportunities associated with 
fungal cell wall and associated targets. 
Fungal cell wall overview for Candida spp. 
The complex fungal cell wall is vital for maintaining cellular shape 
and integrity (Garcia-Rubio et al., 2020). Fungi have a cell wall 
comprising of two layers (inner and outer), which are visible by electron 
microscopy. The composition of the cell wall is subject to change and 
may vary within a single fungal isolate, depending upon the conditions 
and stage of growth, and where glycoprotein, glucan and chitin com-
ponents are extensively cross-linked together to form a complex network 
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(Fig. 1) (Lenardon et al., 2020), forming the overall structural basis of 
the cell wall (Gow and Hube, 2012). 
Inner cell wall compositions for Candida spp 
In most fungal species, the inner cell wall is composed of chitin and 
β-glucans (β-1,3 and β-1,6 linked polymers of glucose) that are linked to 
chitin via β-(1,4) linkages (Lenardon et al., 2020). Chitin is a linear chain 
of β-(1,4)-N-acetylglucosamine and represents the dominant structural 
polysaccharide in the fungal cell wall (Fig. 2). The major synthases that 
make chitin (and glucans) reside in the plasma membrane (PM) and use 
UDP-sugars (Ahmadipour and Miller, 2017) as the sugar donors for the 
formation of a polysaccharide, which is extruded into the cell wall 
(Bowman and Free, 2006; Gow et al., 2017). The sugar nucleotide uri-
dine diphosphate (UDP)-N-acetylglucosamine (from the cytoplasmic 
side of the membrane) is the substrate for chitin synthase which is 
responsible for the synthesis of chitin with molecular weights from 100 
to 130 KDa observed for the final polysaccharide. The gene encoding 
β-(1,3)-D-glucan synthase, FKS1 and FKS2, were initially identified in 
Saccharomyces cerevisiae (Bowen et al., 1992). 
Outer cell wall composition for Candida spp. 
The outer cell wall in Candida spp., including C. albicans, consists of 
layers of highly glycosylated cell wall proteins that are decorated with 
N- and O-linked terminal mannans and phosphomannans (Fig. 1). N- 
Linked glycans often display extensive branching, while O-linked gly-
cans tend to be linear chains of two to six mannose residues and act as a 
mask to hide other glycans (i.e. β-1,3 glucan) (Garcia-Rubio et al., 2020). 
Outer mannan chains do not influence the overall cell shape as they are 
less rigid compared to β-glucans and chitin. However, they impart low 
permeability and porosity to the cell wall, which reduces antifungal drug 
uptake by affecting the resistance of the cell wall to attack by host 
molecules and the permeability of the wall to antifungal drugs, without 
influencing cell shape (Gow and Hube, 2012). Pathogen recognition by 
the innate immune system is crucial to initiate efficient protective im-
mune responses during the fungal infection. Pathogen associated mo-
lecular patterns (PAMPs) are located on the cell wall. Most fungi have O- 
and N-Linked mannosylated PAMPs, considered as PAMP ligands that 
are recognized by a range of C-type lectin receptors (CTLs) (Vendele 
et al., 2020). C-type lectin receptors are a family of pattern recognition 
receptors (PRR) that recognize the structure of the cell surface poly-
saccharides. Multiple CTLs are involved in pathogen recognition of 
fungal cell wall components including β-glucan, chitin, mannan and 
melanin. Dectin-1 recognizes β-1,3-glucan, the conserved element of the 
inner cell wall of most of fungal pathogens. Manno-proteins mask 
β-glucan layer decreasing the recognition of fungi by the host immune 
system, a process that is mediated by Dectin-1, impacting the capacity of 
the host phagocytic cells to uptake and kill Candida cells (Brown et al., 
2002). However, fungal mannans are more complex than glucan, 
comprising linear and branched polymer of mannose linked via α-1,2, 
α-1,3, α-1,4, α-1,6 and β-1,2 glycosidic bonds that may further modified 
by phosphodiester side chain. 
Cell wall composition across Candida spp 
Analysis of cell wall composition across a range of Candida species 
shows largely similar levels of chitin, mannan and glucan, but some 
significant differences are also apparent: C. krusei and C. auris show a 
higher content of chitin when compared to other species, but are also 
different compared to one another (Table 1). Mannan content was 
noticeably higher in C. guilliermondii, with lower levels of glucan. In C. 
albicans, C. krusei, C. tropicalis, and C. auris, O-linked mannans comprised 
about 15% of the total content of cell wall mannan but in C. guillier-
mondii this percentage was over twice that amount. All species showed 
similar levels of cell wall protein, except C. krusei which showed lower 
levels. Cell wall porosity was significantly lower in the walls of 
C. albicans and C. auris (Navarro-Arias et al., 2019). 
Biofilm formation in Candida spp. 
In Candida species, biofilm formation and biofilm-associated drug 
resistance are common, with biofilm formation suggested as a pivotal 
factor for the persistence of Candida in patients and the environment. 
Candida biofilms often resist the effects of available anti-fungal therapies 
and the complex of mannan and glucan is a key component of the bio-
film extracellular matrix (Mitchell et al., 2015). Scanning electron mi-
croscopy has shown that the matrix of C. auris, an emerging multidrug- 
resistant pathogenic fungus that can be transmitted from patient to pa-
tient as a skin colonizer, is rich in mannan-glucan polysaccharides; the 
hydrolysis of which reduces drug tolerance. The analyses of the isolated 
Fig. 1. Structural organization of the Candida albicans cell wall [taken from 
(Lenardon et al., 2020)] using open access article under creative commons 
attribution (CC-BY 4.0) license]. 
Fig. 2. Chemical structure of polysaccharides associated with fungal cell wall. 
A) Chitin B) β-(1,6)-branched β-(1,3)-glucan. 
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extracellular polysaccharide matrix were carried out by gas chroma-
tography. The amount of polymer observed was generally consistent, 
but the content was variable (mean ± standard deviation ratio of 
mannan to glucan = 1.0 ± 0.47). To disrupt the matrix components, the 
biofilm was pretreated with either an α-mannosidase or a β-glucanase. 
The results of susceptibility testing on the biofilms with the antifungal 
(fluconazole) showed that hydrolytic disruption of each matrix poly-
saccharide increased fluconazole susceptibility for all C. auris biofilm 
isolates (Dominguez et al., 2019). Treatment with α-mannosidase 
resulted in a 60% decrease in biofilm burden after exposure to flucon-
azole. Hydrolysis of matrix glucan had less impact, with an average 
biofilm burden reduction of only 25%. These observations support the 
role of matrix mannan and glucan in antifungal drug sequestration 
(Dominguez et al., 2019). 
Biosynthesis of cell wall polysaccharides 
Core polysaccharides: Chitin and β-(1,3)-glucan 
β-(1,3)-Glucans are synthesized at the plasma membrane-bound 
glucan synthase complex, which uses UDP-glucose on its intracellular 
side as a substrate and extrudes linear β-(1,3)-glucan chains through the 
membrane into the cell wall space (Douglas, 2001). After synthesis of 
linear β-(1,3)-glucan, the polysaccharides can be remodeled through the 
combined actions of a specific hydrolase and glucosyltransferase to form 
the modified glucan chains (Fig. 3). This glucan chain becomes cross- 
linked to different polymers such as chitin, leading to the complex 3D 
network of polysaccharides in the fungal cell wall (Yoshimi et al., 2016). 
In contrast, mannans and other decorating polysaccharides such as 
α-(1,3)-glucan and β-(1,6)-glucan are synthesized in the endoplasmic 
reticulum (ER) and Golgi, where they may be conjugated to cell wall 
proteins and transferred to the cell wall by the secretory pathway (Gow 
et al., 2017). 
Cell wall proteins 
Glycosylphosphatidylinositol (GPI) anchors 
Fungal cell walls have multiple proteins with diverse and species- 
specific functions. They play a role in modifying the cell wall proper-
ties, adherence to surfaces and protecting the fungus from harmful 
environmental elements. GPI-anchors are present in eukaryotes and 
anchor a wide variety of proteins to the extracellular part of the plasma 
membrane. In fungi, many of the cell wall synthases, remodeling or 
degrading enzymes, are attached to the outer plasma membrane via a 
GPI unit (Fig. 4) (Yadav and Khan, 2018). In several fungi, C. albicans 
and S. cerevisiae in particular, some of the GPI-anchored proteins (GpiPs) 
are released from the GPI anchor and covalently linked to β-(1,6)- 
glucan, thus being transiently localized at the plasma membrane 
(Richard and Plaine, 2007). 
Fungal cell wall glycoproteins 
Most cell wall proteins are glycoproteins that have passed through 
the secretory pathway in transit to the cell wall. In S. cerevisiae and 
C. albicans, proteins contain roughly 30–50% of the cell wall by dry 
weight (Bowman and Free, 2006). Glycoproteins are extensively modi-
fied with N- and O-linked oligosaccharides and among fungi, the 
structure of the oligosaccharide chains attached to these glycoproteins 
are different. Mannoproteins of the S. cerevisiae and C. albicans cell walls 
Table 1 
Analysis of cell wall composition in Candida species (Navarro-Arias et al., 2019).  
Cell wall abundance    
Organism Chitin (%) Mannan (%) Glucan (%) Protein (µg)a Porosityc (%) Phosphomannan content (µg)b 
C. albicans 2.0 ± 1.3 36.1 ± 4.2 61.7 ± 4.4 146.4 ± 14.9 28.4 ± 8.7d 114.2 ± 14.3 
C. krusei 8.2 ± 1.0d 23.9 ± 2.0d 67.8 ± 2.0 76.4 ± 14.8d 57.7 ± 10.5 66.1 ± 9.0 
C. auris 4.5 ± 1.6d 30.8 ± 1.1 64.9 ± 2.5 138.7 ± 18.2 30.9 ± 9.4d 110.1 ± 15.2 
C. tropicalis 2.3 ± 1.0 36.2 ± 3.5 62.9 ± 5.0 129.7 ± 15.3 62.8 ± 8.9 139.5 ± 19.0d 
C.guilliemondii 2.2 ± 1.0 47.8 ± 4.0d 50.0 ± 5.0d 131.6 ± 18.9 72.3 ± 12.7 131.2 ± 8.9d 
Notes: aµg of protein/mg of cell wall. bµg of alcian blue bound/OD600 = 1. cRelative to diethylaminoethyl (DEAE)-dextran. dP < 0.05, when compared with the values 
from the other species analyzed. Data presented as mean ± SD. Cell cultures were propagated at 30 ◦C in Sabouraud broth (1% [w/v] mycological peptone, 4% [w/v] 
glucose). 
Fig. 3. Putative sequential events in the synthesis and remodeling of β-(1,3) 
glucan.1) Synthesis of linear glucan chains (glucan synthase complex composed 
of a catalytic [GS], FKS/GSC, activating [Act], and RHO1, regulating [Reg] 
subunits). 2) Hydrolysis of glucans. 3) Branching of β-(1,3) glucan. 4) Elonga-
tion of β-(1,3) glucan side chains. 5) Cross-linking with branched [β-(1,3)] 
glucan. Glycosylphosphatidylinositol (GPI)-anchored transglycosidase or hy-
drolases (T) bound to the membrane can act on the polysaccharides in the cell 
wall space [re-produced from (Gow et al., 2017) with permission, license 
number (1131560–1)]. 
Fig. 4. Representative core structure of the Glycosylphosphatidylinositol (GPI) 
structure from GPI-anchored proteins in S. cerevisiae. 
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are glycosylated with chains rich in mannans. In contrast, the glyco-
proteins of A. fumigatus and N. crassa have galactomannan, consisting of 
galactose and mannose residues. Furthermore, some cell wall proteins 
possess a GPI anchor which is added to proteins containing a C-terminal 
signal sequence and act to direct and localize these proteins to the 
plasma membrane and cell wall. Many cell wall proteins are integrated 
into the wall via covalent linkages between the N- and O- linked site of 
the sugar and/or in the GPI anchor with those in chitin or glucan 
(Bowman and Free, 2006). 
Antifungal treatment strategies 
GPI anchor biosynthesis inhibitors 
Anchoring of proteins to the PM through covalent attachment to GPI 
provides an appealing potential target for the development of antifungal 
agents. Proteins designated to be GPI anchored have an N-terminal 
signal sequence for localization to the ER and a C-terminal signal 
sequence for attachment of the GPI anchor. An inhibitor of GPI-anchored 
wall protein transfer 1 (Gwt1), a critical acyltransferase required for the 
biosynthesis of fungal GPI anchors, is a potential antifungal drug target 
(Tsukahara et al., 2003). 1-[4-Butylbenzyl] isoquinoline (BIQ) was 
identified as an inhibitor of the surface expression of GPI-anchored 
mannoproteins in Saccharomyces cerevisiae and C. albicans (Fig. 5A). It 
was demonstrated that the Gwt1 protein, involved in inositol acylation 
of GPI biosynthesis, is a target of BIQ (Umemura et al., 2003). This 
compound also showed the ability to block adherence of C. albicans cells 
to mammalian epithelial cells and inhibits the cell wall assembly of GPI- 
anchored mannoproteins, leading to impaired cell growth in both 
S. cerevisiae and C. albicans. 
Another small molecule, gepinacin (Fig. 5B) selectively inhibits 
Gwt1, without having effect on the viability of mammalian cells or 
inhibiting their orthologous acyltransferase (McLellan et al., 2012). 
Gepinacin was shown to increase the immunogenicity of C. albicans, 
further enhancing its antifungal activity by reducing the mannoprotein 
outer layer of the cell wall and unmasking the immunogenic inner 
β-glucan layer. This resulted in increased recognition of Candida by 
mammalian immune cells. Immunostaining and fluorescence micro-
scopy revealed sublethal concentrations of gepinacin dramatically 
increased β-glucan presentation on the cell surface of C. albicans. 
E1210, 3-(3-{4-[(pyridine-2-yloxy)methyl]benzyl}isoxazol-5-yl) 
pyridine-2-amine (Fig. 5C), acts as an inhibitor of the inositol acylation 
activity of C. albicans Gwt1p, which inhibits the synthesis of GPI and 
hampers the attachment of vital adhesion proteins, such as man-
noproteins to the outer fungal cell wall. E1210 has shown good efficacy 
in the treatment of azole and echinocandin-resistant C. albicans strains 
(Miyazaki et al., 2011). 
β-(1,3)-D-Glucan synthase inhibitor 
β-(1,3)-D-Glucan synthase (GS) is a vital enzyme in the synthesis of 
the essential component of the fungal cell wall, β-(1,3)-D-glucan. Cells 
exposed to echinocandin B (shows morphological changes such as 
swelling and release of intracellular contents (Eshwika et al., 2013). 
Echinocandins act as specific, non-competitive inhibitors of GS. As the 
cell wall is absent in humans/human cells, selective toxicity advanta-
geous for GS inhibitors but the development of resistance to echino-
candins, particularly in Candida spp., is concerning. The resistance 
mechanisms involve amino acid substitutions and naturally occurring 
polymorphisms in hot-spot regions of FKs subunits of glucan synthase, 
cellular stress responses and increased chitin synthesis which decrease 
the sensitivity of the enzyme to drug (Perlin, 2015). 
To overcome the limitations of echinocandins, the effect of orally 
bioavailable triterpene, SCY-078 (Fig. 6C), a glucan synthase inhibitor 
(GSI) was assessed on growth, ultrastructure and biofilm forming ability 
of C. auris (Larkin et al., 2017). SCY-078 has been shown to exhibit both 
in vivo and in vitro activity against common Candida species and is 
currently the only β-(1,3)-glucan synthase inhibitor with both oral and 
intravenous treatment formulations in development (Berkow et al., 
2017). SCY-078 had an MIC90 of 1.0 µg/mL against C. auris and causes 
complete inhibition of growth. Scanning electron microscopy showed 
that SCY-078 disrupted the ultrastructure of C. auris (Fig. 6A and B). 
Fig. 5. Chemical structure of GPI anchor biosynthesis inhibitors A) BIQ B) 
Gepinacin C) E1210. 
Fig. 6. Scanning electron micrograph of C. auris treated with no drug (control) 
A) and with SCY-078 at 1 × MIC (0.5 mg/L) B), The untreated control C. auris 
cells showed a well-defined, oval shaped morphology as well as several budding 
cells. In contrast, cells exposed to SCY-078 showed a severely distorted cell 
topography with cells fused together, indicating they were unable to divide; 
Chemical structure of SCY-078C) [taken from (Larkin et al., 2017) using open 
access article under creative commons attribution (CC-BY 4.0) license]. 
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Candida adhesion inhibition 
As mentioned earlier, adhesion is vital for establishing the Candida- 
host interaction. To infect its host, Candida cells adhere to the host cell 
using adhesions such as agglutinin-like sequence (ALS) proteins (Hoyer 
et al., 1995) and Hwp1 (Sundstrom et al., 2002). After initial adherence, 
contact with the host cell prompts the yeast-to-hypha transition, 
directed growth of the hypha takes place through thigmotropism. 
Invasins, adhesion and physical forces facilitate invasion into the host 
cell which occurs via endocytosis or active penetration (Gow et al., 
2012). Candida albicans binds to glycans at the surface of epithelial cells 
to initiate infection. Aromatic glycoconjugates (AGCs) are small mole-
cules that inhibit C. albicans adherence to buccal epithelial cells (BECs). 
The divalent galactoside with triazolyl group directly linked to the 
anomeric position (Fig. 7) (as a very effective inhibitor of fungal adhe-
sion), built on aromatic molecular scaffolds, is capable of displacing over 
50% of yeast cells already attached to the BECs (Martin et al., 2018). 
Fluorescence imaging indicates that divalent galactosides may bind to 
structural components of the fungal cell wall. 
Lysine-containing cyclodecapeptides are known as regioselectively 
addressable functionalized templates (RAFT) and are used as stable 
scaffolds for the de novo design of peptidomimics. Cyclopeptide and 
dendrimeric polylysine scaffolds are also used to form multivalent dis-
plays of the divalent galactoside glycomimetic (Fig. 7) (Martin et al., 
2021). Adhesion assay studies showed that tetravalent polylysine gly-
codendrimers achieved better results than divalent galactosides, inhib-
iting the fungal adhesion by 64% based on observed scanning electron 
microscopy (SEM) imaging of the morphology of C. albicans cell after 24 
h exposure. 
Peptidyl nucleoside antifungals 
A variety of natural products with antibiotic activities, including 
molecules with polyketide frameworks (erythromycins and tetracy-
clines), oligosaccharide frameworks (aminoglycosides) and those with 
peptide scaffolds, are made by microorganisms (Walsh and Zhang, 
2011). Microorganisms can also join nucleosides to peptide scaffolds to 
generate peptidyl nucleosides, which function as antibiotics. Uridine- 
based nikkomycins and polyoxins are examples of peptidyl nucleosides 
and are fungal chitin synthase inhibitors with fungistatic activities 
(Cabib, 1991). 
Nikkomycins 
Nikkomycins from Streptomyces strains contain two unusual amino 
acids, hydroxypyridylhomothreonine and 5-amino-5-deoxy-hexuronic 
acid, with an N-glycosidically linked base (Ginj et al., 2005). Nikko-
mycin Z (Fig. 8B), a chitin synthase inhibitor, has shown potential for 
therapeutic impact against Candida infections (Chapman et al., 1992). 
The therapeutic potential of nikkomycin Z combined with an echino-
candin (anidulafungin or micafungin) was evaluated against two 
Candida albicans isolates (ATCC 90,028 and blood culture isolate CA 
46503) and laboratory-derived echinocandin-resistant fks mutants 
(FKS1 S645Y and FKS1 S645P). Even though echinocandins are estab-
lished as a front-line treatment for invasive Candida infections, mono-
therapy with nikkomycin Z prolonged the survival of infected mice, but 
the survival rates declined when nikkomycin Z treatment was stopped. 
The fks mutants, derived from the two C. albicans parent strains, were 
homozygous and harbored a single substitution mutation in the fks1 hot- 
spot region. According to the fractional inhibitory concentration index 
(FICI) and minimum inhibitory concentration (MIC) results, the fks 
mutants showed 32-fold elevations in MIC for anidulafungin and mica-
fungin. Synergistic effects with nikkomycin Z and echinocandin were 
observed in the parent strains and the fks mutants. A combination 
treatment with nikkomycin Z and echinocandin showed significantly 
improved survival rate of mice infected with the fks mutants compared 
with that of mice treated with nikkomycin Z or echinocandin mono-
therapy. Only one dosing regimen for nikkomycin Z (at 10 mg/ml twice 
daily) was reported, which was the limitation of this study (Cheung and 
Hui, 2017). 
Chitin synthesis inhibition by a chemical-genetic method 
Chitin is one of the essential components of the fungal cell wall. 
Three chitin synthases, CaChs1p, CaChs2p, and CaChs3p, in C. albicans 
are structurally and functionally analogous to those of S. cerevisiae 
(Sudoh et al., 2000). They are encoded by genes called CaCHS1, CaCHS2 
and CaCHS3. CaCHS1 is essential for the viability of C. albicans and 
Cachs2p is the most abundant protein among the three chitin synthases, 
but it is not vital for viability, hyphal growth or virulence. Both CaChs1p 
and CaChs3p are required for septum formation and cell wall synthesis. 
The fourth chitin synthase in Candida albicans, CHS8 produces class I 
enzyme like that of CHS2 and differs from S. cerevisiae in having two 
isoenzymes in this class (Munro et al., 2003). 
A chemical-genetic method is an approach used to isolate (screen) 
antifungal agents that target chitin synthesis in fungal cells by impairing 
chitin synthesis (Li et al., 2019). Two benzothiazoles (IMB-D10 and IMB- 
F4) (Fig. 8 C and D) have been reported to act as inhibitor of chitin 
synthesis and reducing chitin level in fungal cells (Lucero et al., 2002). 
These compounds showed higher level of toxicity to fungal mutants 
lacking glucan synthase FKs1 compared to wild type (WT) fungal cells 
and mutants lacking chitin synthase CaChs3p. Both inhibit the activity 
of chitin synthase in vitro. IMB-D10 inhibits CaChs1p activity, reduces 
the protein level of the three chitin synthases and shows higher inhibi-
tory activity against C. albicans than IMB-F4. 
Anti-fungal vaccine development 
Despite advances in medicine, there are no licensed vaccines avail-
able to prevent and control human fungal infections (Oliveira et al., 
2021). Reasons for the lack of clinically available fungal vaccines 
include the very high costs related to manufacturing of the antigens, 
toxicology issues and the high cost of conducting clinical trials to 
establish tolerability and safety. In addition, challenges to developing a 
vaccine lie in translating preclinical studies in animals to humans. 
Live-attenuated fungal vaccines 
Vaccines composed of whole organism (live-attenuated or killed 
fungal cells) show high immunogenicity, which makes them most likely 
to generate protective response but there is a potential risk of infection. 
Therefore, inactivated organism and subunit vaccines are safer but 
immunocompromised individuals are less likely to respond to vaccina-
tion. Edward Jenner’s vaccinia virus (the first ever reported vaccine) 
was a live-attenuated vaccine, which caused only a very mild form of the 
disease in humans while at the same time presenting long-lasting pro-
tective immune memory (Wan Tso et al., 2018). 
Recombinant proteins 
In contrast to a prospect of live Candida vaccines, recombinant 
vaccines do not contain any infectious agent and are safer to the human 
host (Wan Tso et al., 2018). This characteristic makes recombinant Fig. 7. Chemical structure of anti-adherence divalent galactosyl AGC.  
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vaccines suitable for immunocompromised individuals. This strategy 
focuses on proteins expressed on the surface of the fungus, such as cell 
wall proteins (CWPs) or adhesion proteins, to ensure that epitopes 
would be easily accessible to the immune system. 
One of the recombinant Candida vaccines, PEV7, has reached human 
clinical testing with promising results (Oliveira et al., 2021). PEV7 
consists of recombinant aspartyl-proteinase 2 (Sap2), a secreted protein 
of Candida albicans, assembled into virosomes. Following observed 
protection in C. albicans-challenged rat model study, a phase 1 clinical 
trial was conducted to assess the safety and immunogenicity of PEV7 in 
48 healthy female volunteers. All of the vaccinated women established 
specific B-cell memory responses (ClinicalTrials.gov identifier: 
NCT01067131) (De Bernardis et al., 2018). 
Synthetic carbohydrate antigens 
Unconjugated oligosaccharides are poorly immunogenic but conju-
gation to a protein carrier enhances their immunogenicity (Xin et al., 
2008). Glycoconjugates from the capsular polysaccharide of pathogenic 
bacteria and carrier proteins, such as tetanus or diphtheria toxoids, have 
been used as effective vaccines (Bundle et al., 2018). These vaccines 
activate T-cells and are effective in reducing the incidence of dangerous 
infectious. Systematic induction of a secondary immune response and 
the recruitment of T helper cells are crucial factors in the success of 
conjugate vaccines. A fully synthetic glycopeptide vaccine (Fig. 9) has 
been constructed from a β-(1,2)-linked mannotriose conjugated to a T- 
cell peptide to obtain the glycopeptide conjugates, which demonstrate 
protection against C. albicans (Xin et al., 2008). 
It was previously thought that the oligosaccharide component of 
conjugate vaccines required ≥ 10 residues, but recent studies prove that 
conjugate vaccines composed of shorter oligosaccharide epitopes are 
also protective. A vaccine candidate derived from a synthetic β-(1,2)- 
linked mannose oligosaccharide hapten conjugated to tetanus toxoid 
could induce high titer antibody, capable of opsonizing the surface of 
C. albicans cells after two injections in an immunocompromised rabbits 
model (Lipinski et al., 2012). Significant reduction of fungal burden in 
animals’ vital organs exhibited after vaccination. These results support 
that this synthetic vaccine was a promising approach to combat fungal 
Fig. 8. Chemical structure of A) UDP-GlcNAc, substrate of chitin biosynthesis B) Uridine-based Nikkomycin as fungal chitin synthase inhibitor C) IMB-D10 and D) 
IMB-F4 inhibit chitin synthase activity against Candida albicans. 
Fig. 9. Structure of synthetic glycopeptide vaccine combining β-mannan and 
peptide epitope shows protection against candidiasis. 
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Plant fungal pathogens and inhibitors 
In plant-fungus interaction, conserved and specific cell wall poly-
saccharides of various fungi, such as chitin are recognised as PAMPs via 
pattern recognition receptor (PRRs) in plants. When fungal pathogen 
invade host plants, recognition of PAMPs triggers immunity in plants 
(PTI). Various cellular defense responses in plants are associated with 
PTI, including generation of reactive oxygen species, reinforcement of 
the plant cell wall and changes in gene expression (Nishimura, 2016). 
Plant diseases cause serious loss of crop production and it is crucial to 
develop novel fungicides to protect crops from fungal plant pathogens. 
Aminopyrifen (Fig. 10A), 4-phenoxybenzyl 2-amino-6-methyl-
nicotinate, showed antifungal activity against Neurospora crassa and 
mycelial growth inhibition was detected at very low concentrations on 
Vogel’s medium containing 1.2% sucrose, with a 0.001 mg/L concen-
tration required for 50% growth inhibition (Hatamoto et al., 2019). To 
identify the target protein for aminopyrifen, resistant mutants were 
isolated and the resistance mutations were localized to the gwt-1 gene 
that encodes Gwt1 and were found to result in S180F and V178A al-
terations in the protein. These results suggest that aminopyrifen acts as 
an inhibitor of Gwt1, a protein involved in GPI-anchored biosynthesis. 
A plant natural product, poacic acid (PA) (Fig. 10B), found in 
lignocellulosic hydrolysates of grasses, has shown to have antifungal 
activity against a range of plant pathogens and against Saccharomyces 
cerevisiae. PA has been reported to target β-(1,3)-glucan synthesis within 
the fungal cell wall (Piotrowski et al., 2015). Poacic acid causes quick 
cell lysis and is synergistic with antifungal drugs that target the cell wall 
and membrane integrity, such as fluconazole and caspofungin. PA also 
shows a species-dependent effect on the human fungal pathogens from 
the genus Candida. Unlike the echinocandins, it inhibits β-(1,3)-glucan 
by directly binding to β-(1,3)-glucan polysaccharide rather than inhib-
iting glucan synthase. (Lee et al., 2018). PA sensitivity is controlled by 
the Ca2+ / calcineurin pathway and susceptibility to PA varies between 
Candida species. The inhibitor effect of PA varies in a range of Candida 
pathogens inhibition, which limits its potential for development as new 
antifungal agent. 
The polyoxins are produced by Streptomyces spp. and exhibit 
powerful bioactivity against phytopathogenic fungi. Polyoxin is known 
to act as a competitive inhibitor of the chitin synthetase (Jackson et al., 
2013) as its structure mimics that of UDP-N-acetylglucosamine (UDP- 
GlcNAc), a substrate for chitin biosynthesis. One of the major compo-
nents of the polyoxin group, polyoxin D (Fig. 10C), is active against 
plant invaders such as the fungus Cochliobolus miyabeanus that causes 
severe leaf spot disease on rice and two North American specialty crops, 
American wildrice and switchgrass (Castell-Miller et al., 2016). Studies 
showed that polyoxin D selectively inhibits the incorporation of 14C- 
glucosamine into the cell wall chitin of Neurospora crassa by approxi-
mately 50%; levels comparable to those required for fungal cell death 
(Endo et al., 1970). This nucleoside derivative also increases accumu-
lation of UDP-GlcNAc, further demonstrating inhibition of chitin 
synthesis. 
Conclusions 
In conclusion, this review summarizes the fungal cell wall compo-
sition across a range of Candida spp. with the focus on synthesis of 
β-glucan and chitin, the core polysaccharides where synthesis is initiated 
at the plasma membrane. Furthermore, the biosynthesis of fungal cell 
wall proteins are described, as they play a role in modifying the cell wall 
properties for adherence to surfaces and protecting the fungal from 
microenvironment. For decades, a variety of fungal cell wall antigens 
(and non-cell wall antigens) have been evaluated in preclinical studies 
and most of these works have been done in mouse models of vaccination, 
followed by challenge of the fungal organism. Three major classes of 
antifungal agents have already been established. However, there is 
scope for direct antifungal activity of novel agents such as small mole-
cules, live-attenuated, recombinant and synthetic vaccines, which could 
help address the challenge of drug-resistant fungi in the near future. 
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